Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor

Journal of Infection and Chemotherapy

Volumn 20, Issue 7, 2014, Pages 401-406

  Nakano, Takashi ^a   Shiosakai, Kazuhito ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Health insurance claims data; Household secondary infection; Influenza; Neuraminidase inhibitor

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ADULT; ARTICLE; DISEASE TRANSMISSION; FEMALE; HEALTH INSURANCE; HUMAN; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; SECONDARY INFECTION; SINGLE DRUG DOSE; ADOLESCENT; FAMILY HEALTH; INFLUENZA, HUMAN; JAPAN; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; ENZYME INHIBITORS; FAMILY HEALTH; FEMALE; HUMANS; INFLUENZA, HUMAN; JAPAN; MALE; NEURAMINIDASE; YOUNG ADULT;

EID: 84903710467     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.01.012     Document Type: Article

References (32)

1. From the Healthy Nippon21 Council Secretariat press release, "Survey on influenza" [accessed 05.04.13], http://www.kenko-nippon21forum.gr.jp/ free/ prerelease/contents034.pdf; November 22, 2011.
2. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283: 1016-24.
3. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355: 1845-50.
4. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza: placebo controlled double-blind multicenter phase III trial. Kansenshogaku Zasshi 2000;74:1044-61 [in Japanese].
5. Matsumoto K, Ogawa N, Nerome K, Numazaki Y, Kawakami Y, Shirato K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antivir Ther 1999;4: 61-8.
6. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Longacting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010;51: 1167-75.
7. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010;54: 2575-82.
8. Watanabe A. A randomized double-blind controlled trial of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 2013;19: 98-102.
9. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012 Feb;10(2): 123-43.
10. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341: 1336-43.
11. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenzaeplacebo-controlled doubleblind multicenter phase III trial. Kansenshogaku Zasshi 2000;74(12): 1062-76.
12. Welliver R, Mont AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA 2001;285: 748-54.
13. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, et al. Management of influenza in households: a prospective, randomized, comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189: 440-9.
14. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults. JAMA 1999;282: 31-5.
15. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000;343: 1282-9.
16. Monto AS, Pichichero ME, Blanckenberg ST, Ruuskanen O, Cooper C, Fleming DM, et al. Zanamivir prophylaxis: effective strategy for the prevention of Influenza types A and B within households. J Infect Dis 2002;186: 1582-8.
17. Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, et al. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 2013 Aug;19(4): 740-9.
18. Yamashita M, Hirai T, Kubota K, Kubo S. Unique characteristics of long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) that explains its long-lasting activity. Influenza Other Respir Viruses 2011;5: 93-5.
19. Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, Komuro I, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J 2013;54(2): 93-7.
20. Wada M, Nakayama T, Ishizaki T, Satoh T, Ikeda S. Practice patterns for lower respiratory tract infections in hospital patients with particular focus on bacteriological examinations and injection antibiotics use. Int J Gen Med 2013;6: 597-604.
21. Furukawa TA, Onishi Y, Hinotsu S, Tajika A, Takeshima N, Shinohara K, et al. Prescription patterns following first-line new generation antidepressants for depression in Japan: a naturalistic cohort study based on a large claims database. J Affect Disord 2013;150(3): 916-22.
22. Onishi Y, Hinotsu S, Furukawa TA, Kawakami K. Psychotropic prescription patterns among patients diagnosed with depressive disorder based on claims database in Japan. Clin Drug Investig 2013;33(8): 597-605.
23. Miura M, Sato K, Muto H, Gopala K, Holl K. Intussusception in Japanese infants: analysis of health insurance claims database. Open J Pediatr 2013;3: 311-6.
24. Pebody RG, Harris R, Kafatos G, chamberland M, Campbell C, Nguyen-Van- Tam JS, et al. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009,United Kingdom. Emerg Infect Dis 2011;17(6): 990-9.
25. National Institute of Infectious Diseases. Infectious diseases weekly report http://www.nih.go.jp/niid/ja/idwr.html [accessed 05.04.13].
26. National Institute of Infectious Diseases. Infectious agents surveillance report http://www.nih.go.jp/niid/ja/iasr.html [accessed 05.04.13].
27. Japan Physicians Association. Influenza manual - 2011-2012 season.
28. From the Healthy Nippon21 Council Secretariat press release, "Survey on influenza" (November 22, 2011).http://www.kenko-nippon21forum.gr.jp/ free/prerelease/contents031.pdf [accessed 05.04.13].
29. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31: 1097-114.
30. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009;63: 596-605.
31. Fujita T, Fujii Y, Watanabe Y, Osaka H, Wada T, Mori M, et al. A pharmacoepidemiologic study on the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza infection. Jpn J Pharmacoepidemiol 2010;15:73-95 [in Japanese].
32. Ishizuka H, Toyama K, Yoshiba S, Okabe H, Furuie H. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Antimicrob Agents Chemother 2012 Jul;56: 3873-8.